Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure
- PMID: 35926931
- DOI: 10.1016/j.jacc.2022.05.027
Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure
Abstract
Background: Ivabradine has potent actions in reducing heart rate and improving clinical outcomes of chronic heart failure with reduced ejection fraction (HFrEF). At present, only the short-acting formulation of ivabradine is available that needs to be administered twice daily.
Objectives: This study sought to evaluate the role of ivabradine hemisulfate sustained release (SR), a novel long-acting formulation of ivabradine dosed once daily, in stable patients with HFrEF.
Methods: Patients with stabilized HFrEF in New York Heart Association functional class II-IV were enrolled and randomized to receive placebo or ivabradine SR in addition to standard medications. The primary endpoint was the change of left ventricular (LV) end-systolic volume index from baseline to week 32.
Results: We randomly assigned 181 patients to placebo and 179 patients to ivabradine SR. After 32 weeks, a significant improvement of LV end-systolic volume index from baseline was observed in both arms with a greater effect in the ivabradine SR arm. Ivabradine SR therapy also exhibited superiority in improving LV end-diastolic volume index, LV ejection fraction, resting heart rate, the Kansas City Cardiomyopathy Questionnaire score, and hospital admission for heart failure worsening and cardiovascular disease in comparison to placebo. Overall adverse events showed no difference between the treatment arms. There were fewer occurrences of worsening heart failure in the ivabradine SR arm.
Conclusions: The present study demonstrates that ivabradine SR once daily in addition to optimum standard therapy improved heart function in patients with HFrEF. (Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets [FIRST]; NCT02188082).
Keywords: chronic heart failure; heart rate; ivabradine; systolic dysfunction.
Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures This work was supported by Jiangsu Hengrui Pharmaceuticals, Lianyungang, China. Jiangsu Hengrui Pharmaceuticals provided the investigational medicinal products and an unrestricted grant. Drs Lou and Cui are full-time employees of Jiangsu Hengrui Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Comment in
-
The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy: Quo Vadis?J Am Coll Cardiol. 2022 Aug 9;80(6):595-597. doi: 10.1016/j.jacc.2022.05.028. J Am Coll Cardiol. 2022. PMID: 35926932 No abstract available.
Similar articles
-
Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.ESC Heart Fail. 2019 Dec;6(6):1199-1207. doi: 10.1002/ehf2.12513. Epub 2019 Oct 8. ESC Heart Fail. 2019. PMID: 31591826 Free PMC article. Clinical Trial.
-
[Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].Zhonghua Xin Xue Guan Bing Za Zhi. 2017 Mar 24;45(3):190-197. doi: 10.3760/cma.j.issn.0253-3758.2017.03.005. Zhonghua Xin Xue Guan Bing Za Zhi. 2017. PMID: 28316174 Clinical Trial. Chinese.
-
Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.Am J Cardiol. 2016 Dec 15;118(12):1948-1953. doi: 10.1016/j.amjcard.2016.08.089. Epub 2016 Sep 15. Am J Cardiol. 2016. PMID: 27780557 Review.
-
I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.Cardiol J. 2015;22(2):227-32. doi: 10.5603/CJ.a2014.0057. Epub 2014 Sep 2. Cardiol J. 2015. PMID: 25179314 Clinical Trial.
-
Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.Am J Cardiovasc Drugs. 2012 Dec 1;12(6):415-26. doi: 10.2165/11209990-000000000-00000. Am J Cardiovasc Drugs. 2012. PMID: 23181944 Review.
Cited by
-
Prolonged elevated heart rate and 90-Day mortality in acute pancreatitis.Sci Rep. 2024 Apr 28;14(1):9740. doi: 10.1038/s41598-024-59557-8. Sci Rep. 2024. PMID: 38679620 Free PMC article.
-
Ivabradine in patients with heart failure: a systematic literature review.J Mark Access Health Policy. 2023 Oct 4;11(1):2262073. doi: 10.1080/20016689.2023.2262073. eCollection 2023. J Mark Access Health Policy. 2023. PMID: 37808119 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials